New Batch of More Mature Biotech Startups Makes Public Market Debut

Wall Street Journal Pro: Venture Capital

"A diverse batch of venture capital-backed biotechnology startups went public Thursday, capitalizing on continued strong interest in the industry, as well as in more mature drugs already in clinical trials or close to being ready to sell."

Read the article (subscription required)

Related Contacts
Marc Recht Partner, Boston
Related Practices & Industries

Public Companies Capital Markets Life Sciences